Report Description of the APAC HIV Diagnostic Market Analysis

Research Scope and Assumption

• The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)


• The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis


• We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses


• All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis


• Inflation has not been accounted for in order to estimate and forecast the market


• Numbers may not add up due to rounding off

Reason to buy the report:

• Facilitate decision-making based on strong current and forecast data for APAC HIV Diagnostic Market Analysis


• Develop strategies based on the latest regulatory framework


• Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market


• Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the APAC HIV Diagnostic Market Analysis


• Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders


• To strategically profile key players and comprehensively analyze their market shares and core competencies


• We have technically sound team which do a deep dive research and also provide strategy based consulting analysis

APAC HIV Diagnostic Market Analysis Executive Summaryc

HIV diagnostics plays a major role in HIV prevention, treatment, care, and other support services. The diagnosis of HIV includes testing services in health-care facilities, free-standing sites, and a wide range of community-based approaches along with HIV self-testing. Developments such as home testing represent new and major opportunities for addressing HIV among men who have sex with men (MSM). According to the UNAIDS, the Joint United Nations Program on HIV and AIDS, 2018 data, Asia Pacific recorded around 5.2 million people living with HIV in 2017.

Market Size and Key Findings

The APAC HIV Diagnostic Market Analysis size stood at around USD 0.75% billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 10.40% during the forecast period.

The size of the Asia Pacific HIV Diagnostics Market is valued at USD 750.72 million in 2020. It is estimated to be growing at a growth rate of 10.40% to reach 1231.19 million by 2028.



Market Dynamics

Market Growth Drivers Analysis

The rise in the spread rate of infectious diseases, the increase in population growth, increased awareness on early screening for diseases and its treatment will increase the market growth, increased set-ups of diagnostic centers, medical centers, clinics, hospitals also increase the market growth. Fully developed infrastructure and healthcare, medical facilities, medical health plans, and schemes, reimbursement policies raise demand for HIV diagnostic market. Government initiatives towards creating awareness in public about safety measures, controlling the rapid spread of infections, maintaining a healthy lifestyle, early screening of diseases, and its treatment increase market size. Rapid growth in clinical examinations and diagnostic tests, easy availability of health screening facilities, affordable range health check-up plans are also increasing market size. An increase in the number of products offers also gears up to market size. Government and non-government funds, public investors are growing demand for this market.

Market Restraints

There are few market restraints held back market growth. Factors such as limited availability of test tools and kits in the market are currently seen, which negatively impacts the market. A few tests and kits are still under clinical investigation. Delayed or slow processing of such activities will hamper the market growth. Noon affordable range of drugs for treatment, hospitality charges are reported as significant patients concerns. However, the government provides beneficial schemes under the healthcare economy, few backward people are still unable to receive these benefits due to lack of awareness on early screening and lifestyle. The low literacy rate is more in this region, and hence due to this, there is more unawareness of disease and diagnosis. This healthy lifestyle is showing an impact on the HIV diagnostics market. The testing procedures and handling needs for professional and skilled workers. Lack of experienced staff will turn out as a negative mark for this market. The high costs of drugs and its side effects are more often a concern for patients, so patients are not readily adaptable to these systems. Testing equipment and devices need to be quality checked and monitored daily. Hence the delay in this process will mask market growth. Fewer times, the tests accuracy is not possible due to testing kit errors or reagent errors. Also, the utilization of reagents and tools are more for carrying out these products.

COVID-19 impact on "APAC HIV Diagnostic Market Analysis

The HIV drugs market has been negatively impacted by the COVID-19 pandemic. Furthermore, as per the industry experts, long-term effects of the COVID-19 outbreak are expected to be witnessed over the coming years. The outbreak has led to a situation of financial crisis in many countries. In addition, failure of suppliers to deliver ARVs (antiretroviral drug) on time, shutdown of land & air transport services, and limited access to health services within countries as a result of the pandemic are anticipated to negatively impact the HIV drugs market in the future.

Competitive Landscape

Key Players

The competitive landscape for the global HIV drugs market has the presence of key market players, such as Viiv Healthcare, Gilead Sciences, Janssen Pharmaceuticals, Inc., and Merck Sharp & Dohme Corp. These companies comprise a major proportion of the market. These key players dominate the HIV market owing to their strong sales of antiretroviral drugs with new product launches and strategic collaborations for the enlargement of their product portfolios. For instance, in March 2021, Gilead Sciences Inc. and Merck Sharp & Dohme entered into an agreement for the co-development and co-commercialization of long-acting treatment with the combinations of Islatravir and Lenacapavir for HIV patients.

Competitive Landscape

Key Players

The competitive landscape for the global HIV drugs market has the presence of key market players, such as Viiv Healthcare, Gilead Sciences, Janssen Pharmaceuticals, Inc., and Merck Sharp & Dohme Corp. These companies comprise a major proportion of the market. These key players dominate the HIV market owing to their strong sales of antiretroviral drugs with new product launches and strategic collaborations for the enlargement of their product portfolios. For instance, in March 2021, Gilead Sciences Inc. and Merck Sharp & Dohme entered into an agreement for the co-development and co-commercialization of long-acting treatment with the combinations of Islatravir and Lenacapavir for HIV patients.

Products in Pipeline

The rising emphasis on R&D activities in the field of HIV drugs is expected to result in the rising drug innovations worldwide. Several reputed companies, such as Boehringer Ingelheim International GmbH, ViiV Healthcare, and Gilead Sciences are engaging in investment initiatives to compete in the market. Some of the others are participating in new product launches and collaborations. In September 2019, for instance, Merck Sharp & Dohme Corp. won the U.S. FDA approval for DELSTRIGO and PIFELTRO combination drugs. These will be used for the treatment of people living with HIV-1. However, many people suffering from this disease across the globe do not have access to timely treatment. It may obstruct the market growth in the near future.

Notable Recent Deals

• In 2014, UNAIDS, the Joint United Nations Program on HIV and AIDS, is engaged in global efforts to end AIDS as a public health threat by 2030 and is a part of the UN Sustainable Development Goal. According to UNAIDS targets, by 2020, 90% of all people living with HIV will know HIV status and 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy. Furthermore, around US$ 3.7 billion was available in 2017 for the AIDS response in Asia Pacific, according to UNAIDS.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

Governments of various countries in Asia Pacific are taking initiatives to create awareness regarding HIV among people due to high prevalence of HIV/AIDS in the region. This in turn is increasing adoption of HIV diagnostic instruments and test kits. Low literacy rate coupled with unawareness regarding transmission mode on HIV, changing lifestyle, and unsafe sex are some of the factors leading to increasing number of HIV cases. In order to lower the disease incidence and increase life expectancy of infected patients, governments of various countries along with NGOs are focusing on improving HIV diagnostics and making them easily accessible to the general population.